Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee

Jeanne Palmer; Jeannine S McCune; Miguel-Angel Perales; David Marks; Joseph Bubalo; Mohamad Mohty; John R Wingard; Angelo Paci; Moustapha Hassan; Christopher Bredeson; Joseph Pidala; Nina Shah; Paul Shaughnessy; Navneet Majhail; Jeff Schriber; Bipin N Savani; Paul A Carpenter

doi:10.1016/j.bbmt.2016.07.013

Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee

Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. doi: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29.

Authors

Jeanne Palmer¹, Jeannine S McCune², Miguel-Angel Perales³, David Marks⁴, Joseph Bubalo⁵, Mohamad Mohty⁶, John R Wingard⁷, Angelo Paci⁸, Moustapha Hassan⁹, Christopher Bredeson¹⁰, Joseph Pidala¹¹, Nina Shah¹², Paul Shaughnessy¹³, Navneet Majhail¹⁴, Jeff Schriber¹⁵, Bipin N Savani¹⁶, Paul A Carpenter¹⁷

Affiliations

¹ Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona. Electronic address: Palmer.Jeanne@mayo.edu.
² Department of Pharmacology University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: jmccune@u.washington.edu.
³ Division of Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Pediatric Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol Royal Infirmary, Bristol, United Kingdom.
⁵ Department of Pharmacy Practice, Oregon Health Sciences University, Portland, Oregon.
⁶ Department of Hematology, Hospital Saint-Antoine, University UPMC, Paris, France.
⁷ Division of Hematology/Oncology, University of Florida, Gainesville, Florida.
⁸ Pharmacology and Drug Analysis Department, Institut de Cancerologie Gustav Roussy, Villejuif, France.
⁹ Department of Clinical Research Centre, Karolinska Institutet, Stockholm, Sweden.
¹⁰ Hematology, Department of Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
¹¹ Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
¹² Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, Texas.
¹³ Adult Blood and Marrow Transplant, Texas Transplant Physician's Group, San Antonio, Texas.
¹⁴ Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio.
¹⁵ Cancer Transplant Institute, Honor Health, Scottsdale, Arizona.
¹⁶ Division of Hematology/Oncology, Vanderbuilt-Ingram Cancer Center, Nashville, Tennessee.
¹⁷ Department of Pediatrics, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.

PMID: 27481448
DOI: 10.1016/j.bbmt.2016.07.013

Abstract

The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation (ASBMT) sought to develop an evidence-based review about personalizing busulfan-based conditioning. The Committee sought to grade the relevant published studies (June 1, 2008 through March 31, 2016) according to criteria set forth by the Steering Committee for Evidence Based Reviews from ASBMT. Unfortunately, the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible. Despite this observation, the continued interest in this topic led the Practice Guidelines Committee to develop a list of most frequently asked questions (FAQs) regarding personalized busulfan dosing. This "Considerations" document is a list of these FAQs and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians.

Keywords: Busulfan; Hematopoietic cell transplantation; Pharmacokinetics; Precision medicine; Therapeutic drug monitoring.

Publication types

Practice Guideline
Review
Research Support, N.I.H., Extramural

MeSH terms

Busulfan / administration & dosage*
Hematopoietic Stem Cell Transplantation / methods
Humans
Myeloablative Agonists / therapeutic use
Precision Medicine / methods*
Transplantation Conditioning / methods*

Substances

Myeloablative Agonists
Busulfan